secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2025-09-04T23:59:59+00:00
Accession:  0001830214-25-000009
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Bioworks enters $100M at-the-market equity sales agreement with Allen & Company
--------------------------------------------------------------------------------

- Up to $100M in Class A common stock may be sold through Agent Allen & Company.
- Agent receives commission of up to 3% of gross proceeds from each sale.
- Registration statement on Form S-3 declared effective August 14, 2025; prospectus supplement dated Sept 4, 2025.
- Net proceeds to be used for general corporate purposes including operations, tech development, working capital.
- Company may terminate Sales Agreement with sufficient written notice; no assurance any shares will be issued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000183021425000009/0001830214-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000183021425000009/dna-20250904.htm
  HTML page:      https://secwatch.observer/filing/0001830214-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer